HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design

mAbs

Volumn 6, Issue 2, 2014, Pages 392-402

  De Goeij, Bart Ecg ^a   Peipp, Matthias ^b   De Haij, Simone ^a   Van Den Brink, Edward N ^a   Kellner, Christian ^b   Riedl, Thilo ^a   De Jong, Rob ^a   Vink, Tom ^a   Strumane, Kristin ^a   Bleeker, WimK ^a   Parren, Paul Whi ^a  

^a GENMAB   (Netherlands)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Antibody drug conjugate; Cancer; HER2; Monoclonal antibody; Pseudomonas exotoxin A

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 MONOCLONAL ANTIBODY; MAB 005; MAB 025; MAB 025MAB 098; MAB 098; MAB 153; MAB 169; MONOCLONAL ANTIBODY; PERTUZUMAB; PSEUDOMONAS EXOTOXIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG CONJUGATION; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; PROTEIN EXPRESSION;

ANTIBODY-DRUG CONJUGATE; CANCER; HER2; MONOCLONAL ANTIBODY; PSEUDOMONASEXOTOXIN A;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIMERIZATION; DRUG DESIGN; ENDOCYTOSIS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; RECEPTOR AGGREGATION; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84896539427     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27705     Document Type: Article

References (48)

1. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16:1647-55; PMID:9130710; http://dx.doi.org/10.1093/ emboj/16.7.1647
2. Tao RH, Maruyama IN. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci 2008; 121:3207-17; PMID:18782861; http://dx.doi.org/10.1242/jcs.033399
3. nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998; 20:41-8; PMID:9504046; http://dx.doi.org/10.1002/(SICI)1521-1878(199801)20:1〈41::AID-BIES7〉3. 0.CO;2-V
4. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75; PMID:19536107; http://dx.doi.org/10.1038/nrc2656
5. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68:9280-90; PMID:19010901; http://dx.doi.org/10.1158/0008-5472.CAN- 08-1776
6. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698-704; PMID:20421541; http://dx.doi.org/10.1200/JCO.2009.26.2071
7. A P. F.D.A. Approves a new drug for advanced breast cancer. The New York Times. New York, 2013.
8. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009; 13:235-44; PMID:19414278; http://dx.doi.org/10.1016/j.cbpa.2009. 03.023
9. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011; 128:347-56; PMID:20730488; http://dx.doi.org/10.1007/s10549-010-1090-x
10. Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15:5268-82; PMID:15385631; http://dx.doi.org/10.1091/mbc.E04-07-0591
11. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073
12. Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005; 116:359-67; PMID:15800944; http://dx.doi.org/10.1002/ijc.21015
13. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008; 314:3093-106; PMID:18793634
14. Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2. Mol Cancer Res 2009; 7:275-84; PMID:19208749; http://dx.doi.org/10.1158/1541-7786.MCR-07-2183
15. Yokoyama WM. Production of monoclonal antibodies. Curr Protoc Cytom 2006; 3(Appendix):3J; PMID:18770829
16. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10. 1038/nature01392
17. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429-40; PMID:19411071; http://dx.doi.org/10.1016/ j.ccr.2009.03.020
18. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http://dx.doi.org/10.1016/S1535- 6108(04)00083-2
19. Landgraf R. HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Breast Cancer Res 2007; 9:202; PMID:17274834; http://dx.doi.org/10.1186/bcr1633
20. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362-71; PMID:16785532
21. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186:1840-8; PMID:21187443; http://dx.doi.org/10.4049/jimmunol.1003032
22. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-37; PMID:12204533; http://dx.doi.org/10.1016/S1535-6108(02)00097-1
23. Kellner C, Bleeker WK, Lammerts van Bueren JJ, Staudinger M, Klausz K, Derer S, Glorius P, Muskulus A, de Goeij BE, van de Winkel JG, et al. Human kappa light chain targeted Pseudomonas exotoxin A - identifying human antibodies and Fab fragments with favorable characteristics for antibodydrug conjugate development. J Immunol Methods 2011; 371:122-33; PMID:21756911; http://dx.doi.org/10.1016/j.jim.2011.06.023
24. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009; 23:1-13; PMID:19344187; http://dx.doi.org/10.2165/00063030-200923010-00001
25. Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI. HER2/neu: mechanisms of dimerization/oligomerization. Oncogene 2000; 19:6093-101; PMID:11156522; http://dx.doi.org/10.1038/sj.onc.1203967
26. rd. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol Cell Biol 2007; 27:2180-8; PMID:17210635; http://dx.doi.org/10.1128/MCB.01245-06
27. Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce CM, Aqeilan RI, Elenius K. Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A 2008; 105:4162-7; PMID:18334649; http://dx.doi.org/10.1073/pnas.0708333105
28. Baulida J, Carpenter G. Heregulin degradation in the absence of rapid receptor-mediated internalization. Exp Cell Res 1997; 232:167-72; PMID:9141633; http://dx.doi.org/10.1006/excr.1997.3515
29. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996; 271:5251-7; PMID:8617810; http://dx.doi.org/10.1074/ jbc.271.9.5251
30. Wiley HS, Herbst JJ, Walsh BJ, Lauffenburger DA, Rosenfeld MG, Gill GN. The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J Biol Chem 1991; 266:11083-94; PMID:1645724
31. Chiron MF, Fryling CM, FitzGerald DJ. Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 1994; 269:18167-76; PMID:8027078
32. Weldon JE, Pastan I. A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011; 278:4683-700; PMID:21585657; http://dx.doi.org/10.1111/j.1742-4658.2011. 08182.x
33. MacDonald GC, Rasamoelisolo M, Entwistle J, Cuthbert W, Kowalski M, Spearman MA, Glover N. A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck. Med Oncol 2009; 26:257-64; PMID:19016010; http://dx.doi.org/10.1007/s12032-008-9111-x
34. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, Pastan I. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 2010; 16:1894-903; PMID:20215554; http://dx.doi.org/10.1158/1078-0432.CCR-09-2980
35. Biggers K, Scheinfeld N. VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. Curr Opin Mol Ther 2008; 10:176-86; PMID:18386230
36. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13:5144-9; PMID:17785569; http://dx.doi.org/10.1158/1078-0432.CCR-07-0869
37. von Minckwitz G, Harder S, Hövelmann S, Jäger E, Al-Batran SE, Loibl S, Atmaca A, Cimpoiasu C, Neumann A, Abera A, et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005; 7:R617-26; PMID:16168106; http://dx.doi.org/10.1186/bcr1264
38. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem 2003; 278:23343-51; PMID:12686539; http://dx.doi.org/10. 1074/jbc.M300477200
39. Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC Jr. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 1999; 82:525-31; PMID:10404066; http://dx.doi.org/10.1002/ (SICI)1097-0215(19990812)82: 4〈525: :AIDIJC10〉3.0.CO;2-J
40. Pastan I, FitzGerald D. Pseudomonas exotoxin: chimeric toxins. J Biol Chem 1989; 264:15157-60; PMID:2504717
41. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997; 14:2099-109; PMID:9160890; http://dx.doi.org/10.1038/sj.onc.1201029
42. Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol 2005; 24:350-8; PMID:15941387; http://dx.doi.org/10.1089/dna.2005.24.351
43. Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B, Hynes NE. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 1995; 60:137-44; PMID:7814146; http://dx.doi.org/10.1002/ijc.2910600120
44. Wehrman TS, Raab WJ, Casipit CL, Doyonnas R, Pomerantz JH, Blau HM. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci U S A 2006; 103:19063-8; PMID:17148612; http://dx.doi.org/10.1073/pnas.0605218103
45. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, Jones D, Kay RM, Higgins KM, Schramm SR, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996; 14:845-51; PMID:9631008; http://dx.doi.org/10.1038/nbt0796-845
46. Kozak M. Initiation of translation in prokaryotes and eukaryotes. Gene 1999; 234:187-208; PMID:10395892; http://dx.doi.org/10.1016/S0378-1119(99)00210- 3
47. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y) 1992; 10:169-75; PMID:1369477; http://dx.doi.org/10.1038/nbt0292-169
48. Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, Houtkamp M, Schuurman J, van de Winkel JG, Parren PW. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006; 66:7630-8; PMID:16885363; http://dx.doi.org/10.1158/0008-5472.CAN-05-4010